THE INVESTOR

메뉴열기
June 18, 2024

Samsung Bioepis to initiate phase 3 trials of Lucentis biosimilar

PUBLISHED : September 20, 2017 - 16:51

UPDATED : September 20, 2017 - 16:51

  • 본문폰트 작게
  • 본문폰트 크게
  • 페이스북
  • sms

[THE INVESTOR] Korea’s biopharmaceutical firm Samsung Bioepis is set to begin late-stage clinical trials of its copy version referencing Novartis’ eye drug Lucentis in Korea

The Ministry of Food and Drug Safety approved the initiation of phase 3 clinical trials of the biosimilar candidate SB11 on Sept. 18. 




The study will be conducted on 140 patients with wet age-related macular degeneration to compare efficacy and safety between SB11 and Lucentis. The brand name drug posted global sales of US$3.3 billion in 2016.

Lucentis has long been targeted by Korean bio startups like BIOCND and Polus, which jumped on the biosimilar bandwagon to make a copy.

To fend off the competition, Novartis has been pushing to expand indications of Lucentis.

In the latest upgrade, the US Food and Drug Administration approved the eye treatment for all forms of diabetic retinopathy in April.

By Park Han-na (hnpark@heraldcorp.com)

  • 페이스북
  • sms
최상단으로
COPYRIGHT HERALD CORPORATION. ALL RIGHTS RESERVED.